Loncar Cancer Immunotherapy Index Conducts Semi-Annual Rebalance

 

Nine Biotechnology Companies Added to the Index

 

Lenexa, KS -- June 16, 2020 -- Loncar Investments, LLC today announced the result of the semi-annual rebalance and reconstitution of the Loncar Cancer Immunotherapy Index, a stock index of top companies developing cancer immunotherapy treatments and discovering new ways to use the body’s immune system to fight cancer.

The Committee has chosen during this meeting to increase the target number of index components to 30 from 25. This change reflects the committee’s belief that the science of immunotherapy is strengthening and the pool of quality available companies is growing. The committee has been encouraged to see recent data releases in areas such as bi-specific antibodies, allogenic CAR-T, CD47, cytokines, oncolytic viruses, TIGIT, and others. 

For the June meeting, the committee has added nine new immunotherapy companies. They are Adaptimmune (Nasdaq: ADAP), Arcus Biosciences (NYSE: RCUS), Compugen (Nasdaq: CGEN), Cue Biopharma (Nasdaq, CUE), IGM Biosciences (Nasdaq: IGMS), Legend Biotech (Nasdaq: LEGN), MacroGenics (Nasdaq: MGNX), Replimmune (Nasdaq: REPL), and Trillium Therapeutics (Nasdaq: TRIL).

 

These companies replace Atara Biothearpeutics (Nadaq: ATRA), Autolus Therapeutics (Nasdaq: AUTL), Precision Biosciences (Nasdaq: DTIL), and Ziopharm Oncology (Nasdaq: ZIOP).

“Our decision to increase the index’s number of components during this period is based on our committee’s positive opinion of the progress being made in immunotherapy science.” said Brad Loncar, CEO of Loncar Investments and Chairman of the index committee. “We are pleased to support this expanded field of companies as they aim to deliver new innovations for patients.”

 

Effective this week, all index holdings have been rebalanced to hold equal weight. The index is rebalanced and reconstituted semi-annually. The next rebalance will occur on December 15, 2020. 

 

Loncar Investments is an official partner of the Cancer Research Institute, the world’s longest running nonprofit organization dedicated exclusively to harnessing the immune system’s power to conquer all cancers. To learn about how to give to CRI, please visit here .

 

Why immunotherapy:  Cancer immunotherapy has become an important sector in the biotechnology space and is changing the way many cancers are treated. While traditional medicines like chemotherapies often give cancer a broad punch, the benefit of using immunotherapy is derived from the immune system's dynamic nature and the way it can more precisely be tailored to fight a patient's disease.  

 

About the index:  The Loncar Cancer Immunotherapy Index is an equal-weighted index of top immunotherapy companies rebalanced and reconstituted on a semi-annual basis. Price and return data are independently calculated on a daily basis by Indxx, LLC. Additional information can be found at the index’s dedicated website, www.LoncarIndex.com.

 

Index provider:  Loncar Investments, LLC is committed to making the biotechnology space more approachable to a wider range of investors. It incorporates extensive research into biotech companies and technologies to develop stock market indexes that are focused on precise investment opportunities. The company is principally owned by biotech investor and analyst Brad Loncar.

 

 

Contact:

Loncar Investments, LLC

Jill Tatios, 215-240-6398

Email: loncar@gregoryfca.com

Loncar Investments, LLC : P.O Box 15072, Lenexa, KS  66285 : 913-871-5007 : Not investment advice or a solicitation to buy or sell securities